CD19 and B-cell acute lymphoblastic leukemia: In contrast, blinatumomab (CD19/CD3; B-cell acute lymphoblastic leukemia), a non-BCMA bispecific T-cell engager, was associated with a variety of cutaneous reactions including eczema, psoriasis, seborrheic dermatitis, acne, folliculitis, dermatitis, and panniculitis.9